Provision Language
9. CureVac and BMGF acknowledge and agree that any Patents and Know-How resulting from the development of the BMGF [*****] Vaccines will be Controlled by CureVac and shall form part of the licensed CureVac Technology (as defined in the CLA on the Effective Date) at no additional cost or royalty to GSK.